← Back

SFJ III (Pfizer)

SFJ-NSCLC and Pfizer collaborated on a Phase III trial of Pfizer's VIZIMPRO® (dacomitinib) for the treatment of non-small cell lung cancer (NSCLC). The kinase inhibitor is approved in the US, China and Japan for the treatment of NSCLC

LocationPleasanton, California
CEORobert DeBenedetto
Partner Shelley Chu , Ken Haas
Websitewww.sfj-pharma.com